valsartan has been researched along with Diabetes Mellitus in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (22.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (24.00) | 29.6817 |
| 2010's | 10 (20.00) | 24.3611 |
| 2020's | 17 (34.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y; Liu, C; Yu, M | 1 |
| Abadir, PM; Antonio, MJ; Boronina, T; Cole, R; Cui, H; Foster, DB; Jedrych, J; Le, A; Li, Y; Lin, R; Marin, S; Nidadavolu, LS; Rini, D; Smith, B; Stern, D; Talbot, C; Walston, JD; Wang, Y; Wu, Y; Yenokyan, G | 1 |
| Nolan, T | 1 |
| Chen, H; Chen, X; Guan, F; Han, S; Huang, S; Huang, Z; Li, H; Lin, W; Wang, Y; Ye, F | 1 |
| Heerspink, HJL; Ter Maaten, JM; Voordes, GHD | 1 |
| Claggett, B; Cunningham, JW; Jackson, A; Lefkowitz, M; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Rørth, R; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Wijkman, MO; Zile, M | 1 |
| Polovina, M; Rosano, G; Seferović, J; Seferović, PM | 1 |
| Belohlavek, J; Butylin, D; Chiang, Y; Fonseca, C; Lonn, E; Noè, A; Pascual-Figal, D; Schwende, H; Senni, M; Straburzynska-Migaj, E; Wachter, R; Witte, KK | 1 |
| Abumayyaleh, M; Akin, I; Aweimer, A; Crack, C; Demmer, J; El-Battrawy, I; Mügge, A; Pilsinger, C; Zhou, X | 1 |
| Wang, L; Wang, R; Wang, Y; Wei, J; Ye, H; Zhang, X; Zhao, Y | 1 |
| Ai, SS; Cui, T; Gao, RR; Han, C; Hu, HZ; Li, W; Liu, Y; Shen, Z; Sui, GY | 1 |
| Ding, Y; Duan, FY; Huang, SL; Jia, PP; Ren, XQ; Song, CD; Song, D; Wang, YX; Zhai, WS | 1 |
| Harada, N; Kato, T; Murakami, T; Yabe, D | 1 |
| Hu, L; Liu, G; Wei, Y | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| 't Hart, DC; Danser, AHJ; de Vries, R; Garrelds, IM; Groningen, MCC; Hoorn, EJ; Joles, JA; Nijenhuis, T; Roksnoer, LCW; Uijl, E; van der Vlag, J; van Veghel, R; Zietse, R | 1 |
| Abdel-Moneim, RA; El-Salamouni, NS; Gowayed, MA; Kamel, MA; Labib, GS; Seiffein, NL | 1 |
| Abraham, I; Alkhatib, N; Brié, H; Denhaerynck, K; Hamarneh, D; MacDonald, K; Sun, D; Van Camp, Y; Vancayzeele, S; Villa, L | 1 |
| Fernández-Ruiz, I | 1 |
| Gaikwad, AB; Malek, V | 1 |
| Brancati, FL; Califf, RM; Chatterjee, R; Edelman, D; Svetkey, L; Thomas, L | 1 |
| Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O | 1 |
| Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Braga, MF; Leiter, LA | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Brown, RE; Imran, SA; Wilkinson, M | 1 |
| Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A | 1 |
| Ando, H; Fujimura, A; Ishikawa-Kobayashi, E; Maekawa, T; Nozawa, M; Shiga, T; Takuma, M; Ushijima, K | 1 |
| Al Balushi, KA; Al-Zakwani, I; Habib, JQ | 1 |
| Krum, H; Martin, J | 1 |
| GIRAUD, G; PUECH, A | 1 |
| BERNARD, J | 1 |
| LABORIE, P | 1 |
| UZAN, M | 3 |
| BOULIN, R | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Takeuchi, M; Yamagishi, S | 1 |
| Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Amerena, J; Balazovjech, I; Brunner, HR; Cassel, G; Herczeg, B; Hua, TA; Julius, S; Kjeldsen, SE; Koylan, N; Laragh, J; Magometschnigg, D; Majahalme, S; Martinez, F; McInnes, GT; Oigman, W; Schork, MA; Seabra Gomes, R; Weber, MA; Zanchetti, A; Zhu, JR | 1 |
| Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D | 1 |
| Dunseath, G; Luzio, SD; Owens, DR | 1 |
6 review(s) available for valsartan and Diabetes Mellitus
| Article | Year |
|---|---|
Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Hypoglycemia; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
Topics: Aminobutyrates; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Humans; Neprilysin; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2017 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
10 trial(s) available for valsartan and Diabetes Mellitus
| Article | Year |
|---|---|
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Heart Failure; Humans; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Topics: Antihypertensive Agents; Biomarkers; Cyclohexanes; Diabetes Mellitus; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Potassium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension; Incidence; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Valsartan for prevention of recurrent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2009 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan | 2005 |
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output, Low; Diabetes Mellitus; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk; Tetrazoles; Valine; Valsartan | 2006 |
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan | 2002 |
34 other study(ies) available for valsartan and Diabetes Mellitus
| Article | Year |
|---|---|
Effects of calcium dobesilate combined with categlicine and valsartan capsules on inflammation and cellular immunity in patients with diabetic nephropathy.
Topics: Calcium Dobesilate; Capsules; Diabetes Mellitus; Diabetic Nephropathies; Humans; Immunity, Cellular; Inflammation; Valsartan | 2023 |
Valsartan nano-filaments alter mitochondrial energetics and promote faster healing in diabetic rat wounds.
Topics: Animals; Diabetes Mellitus; Humans; Hydrogels; Rats; Rats, Zucker; Valsartan; Wound Healing | 2021 |
Tom Nolan's research reviews-26 November 2021.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Cats; COVID-19; COVID-19 Serotherapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dogs; Drug Combinations; Gastric Inhibitory Polypeptide; Heart Sounds; History, 20th Century; Humans; Hypertension; Immunization, Passive; Incretins; Insulin Glargine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; SARS-CoV-2; Thiazides; Valsartan | 2021 |
Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Kidney; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus; Enalapril; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemia; Insulins; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Diabetes Mellitus; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Troponin I; Valsartan; Ventricular Function, Left | 2023 |
Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis".
Topics: Animals; Blood Glucose; Chromatography, Liquid; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glycerophospholipids; Herbal Medicine; Kidney; Rats; Saline Solution; Sphingolipids; Tandem Mass Spectrometry; Tryptophan; Valsartan | 2023 |
[Effect of multi-glycosides of Tripterygium wilfordii on renal injury in diabetic kidney disease rats through NLRP3/caspase-1/GSDMD pyroptosis pathway].
Topics: Animals; Caspase 1; Diabetes Mellitus; Diabetic Nephropathies; Glycosides; Interleukin-18; Kidney; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tripterygium; Uridine Triphosphate; Valsartan | 2023 |
Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; C-Peptide; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2023 |
Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension.
Topics: Biphenyl Compounds; Delayed-Action Preparations; Diabetes Mellitus; Diabetic Nephropathies; Drug Combinations; Humans; Hypertension; Nifedipine; Tetrazoles; Valsartan | 2023 |
Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus; Drug Combinations; Hypertension; Male; Neprilysin; Podocytes; Protective Agents; Rats; Tetrazoles; Valsartan | 2020 |
Valsartan solid lipid nanoparticles integrated hydrogel: A challenging repurposed use in the treatment of diabetic foot ulcer, in-vitro/in-vivo experimental study.
Topics: Animals; Anti-Bacterial Agents; Diabetes Mellitus; Diabetic Foot; Drug Carriers; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrogels; Lipids; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Valsartan; Vascular Endothelial Growth Factor A | 2021 |
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Models, Statistical; Prospective Studies; Risk Factors; Valsartan | 2021 |
Diabetes: Sacubitril/valsartan improves glycaemic control.
Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Enalapril; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Cortex; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pituitary Gland; Resistin; RNA, Messenger; Subcutaneous Fat; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult | 2011 |
Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Topics: Adiponectin; Adipose Tissue; Animals; Benzimidazoles; Benzoates; Body Weight; Diabetes Mellitus; Eating; Fatty Acid Synthases; Fatty Acid-Binding Proteins; Gene Expression Regulation; Homeostasis; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Obese; PPAR gamma; RNA, Messenger; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Male; Middle Aged; Oman; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2013 |
[The treatment of diabetes at Vals-les-bains].
Topics: Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1952 |
[Congress of diabetes mellitus; Vals-les-Bains, 15-18 September 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1952 |
[Diabetes Congress at Vals].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1952 |
[Diabetes; Vals-les-Bains, September 14-18, 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1953 |
[Conference on diabetes in Vals-les-Bains, 14-18 September, 1952].
Topics: Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1953 |
[Diabetes in 1953; the Congress of Vals].
Topics: Burns; Diabetes Mellitus; Tetrazoles; Valine; Valsartan | 1953 |
[Diabetic center at the Vals-les-Bains Hospital].
Topics: Diabetes Mellitus; Health Facilities; Hospitals; Humans; Tetrazoles; Valine; Valsartan | 1955 |
[APROPOS OF THE H OPITAL-CENTRE DE DIABETOLOGIE DE VALS].
Topics: Diabetes Mellitus; Hospitals; Valsartan | 1963 |
[Mineral water cure Vals-les-Bains in the treatment of diabetes mellitus].
Topics: Bicarbonates; Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1955 |
[Diabetes cure at Vals-les-Bains, based on recent research].
Topics: Balneology; Diabetes Mellitus; Humans; Tetrazoles; Valine; Valsartan | 1951 |
[Vals-les-Bains cure in diabetics].
Topics: Diabetes Mellitus; Humans; Mineral Waters; Tetrazoles; Valine; Valsartan | 1951 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tetrazoles; Time Factors; Treatment Outcome; United States; Valine; Valsartan | 2007 |